News Release

October 30, 2024
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Personnel Change

Hyogo, Japan, October 30, 2024 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") hereby announces that its Board of Directors resolved at a meeting held today to change personnel change as follows.

1. Executive Officer Personnel Assignment (As of November 1, 2024)

Name	New Title	Current Title
Toshihiro Ishikiriyama	Senior Managing Executive Officer, Executive Director, Business Development Division	Senior Executive Fellow, Business Development

2. General personnel assignment (As of November 1, 2024)

Name	New Title	Current Title
Hiroshi Kagoshige	Director, Business Development	Executive Director, Business Development Division(Acting Director), Director, Business Development

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###